CERO Therapeutics Holdings, Inc. announced on July 31, 2025, that it has dosed the second patient in the first cohort of its Phase 1 CER-1236 clinical trial for acute myeloid leukemia (AML). The patient was dosed at the Sarah Cannon Research Institute (SCRI) at Colorado Blood Cancer Institute (CBCI).
Monitoring for key safety, tolerability, and efficacy endpoints continues for the second patient, more than seven days post-infusion. This milestone follows the previous report that the first patient treated in the CertainT-1 trial experienced no dose-limiting toxicities during the 28-day observation period.
Further analysis of CER-1236 pharmacokinetics in the first patient revealed a rapid and significant 20.8-fold expansion of infused cells, peaking at 14 days post-infusion. CEO Chris Ehrlich expressed encouragement at this robust cell expansion, stating it is a positive sign that the company is on the right track in its Phase 1 study, based on extensive experience in CAR T cell development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.